Biotech funding in a cold climate
This article was originally published in Scrip
Executive Summary
Yesterday was the 92nd anniversary of the signing of the armistice that brought the hostilities of the First World War formally to an end. Coincidentally, it also marked the re-emergence of the UK-based regenerative medicine company Intercytex, which announced that its lead product, the cell therapy Vavelta, is to be evaluated by the US military to help treat injured soldiers.